Generics Drugs - news, views, reports

A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration,...

Novartis

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals,...

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

Celgene edges higher on Abraxane melanoma study

Shares of Celgene Corp. rose Tuesday after the company said its cancer drug Abraxane slowed the progression of melanoma in a late-stage clinical trial.The trial compared Abraxane and dacarbazine in 5...

Oncology Spotlight: Abraxane May Earn Approval for Third Indication

Celgene Corp. recently released positive Phase 3 data for its cancer drug Abraxane in combination with gemcitabine (Lilly’s chemotherapy drug) for the treatment of advanced pancreatic cancer.  The...

Celgene gets new Abraxane marketing approval

Celgene Corp. said Friday it won a new marketing approval for its drug Abraxane. The Food and Drug Administration approved it as a primary treatment for non-small cell lung cancer.Abraxane was approv...

US FDA Grants Approval For Celgene's ABRAXANE For Non-Small Cell Lung Cancer

SUMMIT (dpa-AFX) - Celgene Corporation (CELG) Friday announced that the U.S. Food and Drug Administration, or the FDA has approved ABRAXANE for the first-line treatment of locally advanced or meta...

Abraxane meets endpoint in first-line metastatic melanoma

Celgene Corp. (NASDAQ:CELG) said Abraxane nab-paclitaxel met the primary endpoint of progression-free survival (PFS) vs. dacarbazine in the Phase III CA033 trial in 529 chemotherapy-naive patients wit...

Celgene's melanoma drug Abraxane prolongs survival in study

Previously untreated patients with metastatic melanoma who received Celgene's Abraxane, or paclitaxel, achieved progression-f -More- 

Celgene seeks FDA approval of Abraxane for pancreatic cancer

Celgene plans to submit Abraxane, or paclitaxel, within the next five months for FDA approval as a treatment for pancreatic c -More- 

Celgene's Abraxane Increases Survival In Advanced Pancreatic Cancer

SUMMIT (dpa-AFX) - Celgene International Sàrl, a subsidiary of Celgene Corp. (CELG), announced that its phase III clinical trial of abraxane (paclitaxel protein-bound particles for injectable susp...

A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.

Cellax is a PEGylated carboxymethylcellulose conjugate of docetaxel (DTX) which condenses into a 120-nm nanoparticle, and was compared against the approved clinical taxane nanoformulation (Abraxane®)...

Patients' attitudes towards generic drug substitution in Japan.

OBJECTIVE: The aim of this study was to evaluate the understanding and attitude of Japanese patients towards generic drug substitutions. METHOD: The subjects were male and female patients, who purchas...

Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus.

Glycopeptide antibiotics, such as vancomycin and teicoplanin, have been used worldwide to treat infection caused by methicillin-resistant Staphylococcus aureus (MRSA). Generic teicoplanin products wer...

Generic drugs in morocco: survey of physicians.

Objective. To assess the knowledge of physicians about generic drugs and their prescribing habits, with a view to making proposals for developing the use of generic drug in Morocco...

Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?

Background: In many countries with generic reference pricing, generic producers and distributors compete by means of undisclosed discounts offered to pharmacies in order to reduce acquisition costs an...